| Name | ENMD-2076 |
|---|---|
| Synonyms |
ENMD-2076
MFCD18074523 KXQ762CQTH (2R,3R)-2,3-Dihydroxysuccinic acid - 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylvinyl]-4-pyrimidinamine (1:1) Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]-4-pyrimidinamine (1:1) MFCD18633211 |
| Description | A multitargeted kinase inhibitor with IC50s of 3/14/23/40 nM for Flt3/Aurora A/Src/VEGFR2. |
|---|---|
| In Vitro | A multitargeted kinase inhibitor with IC50s of 3/14/23/40 nM for Flt3/Aurora A/Src/VEGFR2; also inhibits Aurora B, c-Kit, FGFR1 (IC50=100-350 nM); orally bioactive.Liver CancerPhase 2 Clinical |
| Molecular Formula | C25H31N7O6 |
|---|---|
| Molecular Weight | 525.557 |
| Exact Mass | 525.233582 |